All Stories

  1. Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes

    Article • Leukemia, March 2026, Springer Science + Business Media

    MD Mikhail Fominykh

  2. CML-155 Prognostic Markers of the Effectiveness of Tyrosine Kinase Inhibitors in Third-Line Therapy of Chronic Phase Chronic Myeloid Leukemia Patients: Data From a Multicenter Study

    Article • Clinical Lymphoma Myeloma & Leukemia, October 2022, Elsevier

    MD Mikhail Fominykh

  3. Current Quality-of-Life Aspects in Patients with Classical Ph-Negative Myeloproliferative Neoplasms in the Russian Federation: Overview of the Outcomes of the National Observational Program MPN-QoL-2020

    Article • Clinical oncohematology, January 2022, Practical Medicine Publishing House

    MD Mikhail Fominykh

  4. Efficacy Predictors of the Third-Line Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase of Chronic Myeloid Leukemia: Results of a Multi-Center Study

    Article • Clinical oncohematology, January 2022, Practical Medicine Publishing House

    MD Mikhail Fominykh

  5. Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update

    Article • Leukemia, May 2021, Springer Science + Business Media

    MD Mikhail Fominykh

  6. Peculiarities of plasma hemostasis in patients with Ph-negative myeloproliferative neoplasms

    Article • Тромбоз гемостаз и реология, September 2020, Cifra Ltd - Russian Agency for Digital Standardization (RADS)

    MD Mikhail Fominykh

  7. Withdrawal Syndrome After Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia in the Russian Prospective Study RU-SKI

    Article • Clinical Lymphoma Myeloma & Leukemia, May 2020, Elsevier

    MD Mikhail Fominykh

  8. Development and Validation Results of the Russian MPN10 Form for Symptom Assessment in Patients with Myeloproliferative Neoplasms in Compliance with International Recommendations

    Article • Clinical oncohematology, January 2020, Practical Medicine Publishing House

    MD Mikhail Fominykh

  9. PB2217 EPIDEMIOLOGICAL, CLINICAL, MOLECULAR AND GENETIC CHARACTERISTICS OF PRIMARY MYELOFIBROSIS IN THE RUSSIAN FEDERATION

    Article • HemaSphere, June 2019, Wiley

    MD Mikhail Fominykh

  10. PB2206 HEMOSTATIC MARKERS OF HYPERCOAGULABILITY IN PRIMARY MYELOFIBROSIS PATIENTS, RELATION WITH JAK2V617F ALLELE BURDEN

    Article • HemaSphere, June 2019, Wiley

    MD Mikhail Fominykh

  11. PB2197 NEXT-GENERATION SEQUENCING IN CLINICAL PRACTICE: MOLECULAR EVENTS AND COURSE OF MYELOPROLIFERATIVE NEOPLASMS

    Article • HemaSphere, June 2019, Wiley

    MD Mikhail Fominykh

  12. PB2232 THE NATURAL ANTICOAGULANTS IN PATIENTS WITH PHILADELPHIA‐NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

    Article • HemaSphere, June 2019, Wiley

    MD Mikhail Fominykh

  13. Role of FLT3 gene mutations in acute myeloid leukemia: effect on course of disease and results of therapy

    Article • Genes and Cells, March 2019, ECO-Vector LLC

    MD Mikhail Fominykh

  14. Current Genetic Models for Prediction of Primary Myelofibrosis

    Article • Clinical oncohematology, January 2019, Practical Medicine Publishing House

    MD Mikhail Fominykh

  15. Role of Molecular Drivers in Coagulation By Integral Assessment in Primary Myelofibrosis Patients

    Article • Blood, November 2018, American Society of Hematology

    MD Mikhail Fominykh

  16. Russian Experience of Bosutinib Use in Chronic Myeloid Leukemia Patients in Routine Clinical Practice

    Article • Blood, November 2018, American Society of Hematology

    MD Mikhail Fominykh

  17. Clinical Experience and Perspectives of Bosutinib Use in Patients with Chronic Myeloid Leukemia

    Article • Clinical oncohematology, January 2018, Practical Medicine Publishing House

    MD Mikhail Fominykh

  18. Results of following up patients with chronic myeloid leukemia and a deep molecular response without tyrosine kinase inhibitor therapy

    Article • Terapevticheskii arkhiv, December 2017, LLC Obyedinennaya Redaktsiya

    MD Mikhail Fominykh

  19. Targeted Therapy of Myelofibrosis

    Article • Clinical oncohematology, January 2017, Practical Medicine Publishing House

    MD Mikhail Fominykh

  20. GROUP OF AUTHORS UNDER THE SUPERVISION OF ACADEMICIAN VG SAVCHENKO

    Article • Clinical oncohematology, January 2017, Practical Medicine Publishing House

    MD Mikhail Fominykh

  21. Molecular Genetic Markers and Clinical Characteristics of Essential Thrombocythemia

    Article • Clinical oncohematology, January 2017, Practical Medicine Publishing House

    MD Mikhail Fominykh

  22. THROMBOTIC AND BLEEDING RISK FACTORS IN ESSENTIAL THROMBOCYTHEMIA

    Article • Oncohematology, January 2017, Publishing House ABV Press

    MD Mikhail Fominykh

  23. Genetic Markers of Hereditary Thrombophilia and Risk of Thrombotic Complications in Patients with Polycythemia Vera

    Article • Clinical oncohematology, January 2017, Practical Medicine Publishing House

    MD Mikhail Fominykh

  24. The combination treatment regimen of ruxolitinib in frail patients with blast-phase myelofibrosis

    Article • British Journal of Haematology, June 2016, Wiley

    MD Mikhail Fominykh, Mrs Lyubov' Polushkina

  25. Combination therapy with ruxolitinib plus low-dose cytarabine or mercaptopurine in patients with blast-phase myelofibrosis

    Article • Oncohematology, January 2016, Publishing House ABV Press

    MD Mikhail Fominykh

  26. Chronic Myeloid Leukemia: Long-Term Experience of Target Therapy

    Article • Clinical oncohematology, January 2016, Practical Medicine Publishing House

    MD Mikhail Fominykh

  27. Transplantation of Mesenchymal Stem Cells in Multiple Sclerosis

    Article • Neuroscience and Behavioral Physiology, June 2012, Springer Science + Business Media

    MD Mikhail Fominykh

  28. Romiplostim After Autologous Peripheral Blood Progenitor Cell Transplantation: Results of a Pilot Study

    Article • Biology of Blood and Marrow Transplantation, February 2012, Elsevier

    MD Mikhail Fominykh